Increasing evidence from preclinical and clinical studies indicates that suppressing AR activity is beneficial for the treatment of DN [19]; aldose reductase inhibitors (ARIs) may arrest or even reverse the progression of DN. Here, AR is linked to liver dysplastic nodule.